Learn More Today
Living Pharma develops Personalized CAR T Cell Therapy™tailored to the individual patient's cancer and disease phenotype.
Lentigen Technology Inc., a Miltenyi Biotec Company, Acquires University of Maryland, Baltimore CAR-T Cell Start-Up, Living Pharma, Inc.
Lentigen Technology Inc., a leading provider of GMP lentiviral vectors, will further advance Living Pharma’s personalized chimeric antigen receptor (...
July 20, 2017
Living Pharma Adds Noted Oncologist to its Advisory Board
Living Pharma, Inc. announced today that it has added Aaron P. Rapoport, MD, to its advisory board.
November 1, 2016
Living Pharma Adds Venture Capital Executive to its Advisory Board
Living Pharma, Inc. announced today that it has added Isai Peimer, PhD, to its advisory board.
June 1, 2016
Living Pharma Signs Exclusive License Agreement with UMB for a Novel Universal CAR T Cell Platform Technology
Living Pharma, Inc. announced today that it has entered into an exclusive license agreement with the University of Maryland, Baltimore (UMB) to...
January 28, 2016
firstname.lastname@example.org general email
To learn more about Living Pharma and our investor opportunities, please complete our contact form.